@article{33caa5fce6e24fdd874035465dc1589a,
title = "Combined effects of HIV and obesity on the gastrointestinal microbiome of young men who have sex with men",
abstract = "Objectives: The prevalence of obesity is rising among people living with HIV, which may synergistically increase inflammation and the risk of associated diseases. Disruption of gut bacterial communities may be one of the key drivers of this inflammation; however, the combined effects of HIV and obesity on the microbiome have not been explored. Methods: This study included 381 men who have sex with men. Thirty-nine were HIV-positive and obese (H+O+), 143 were HIV-positive and nonobese, 64 were HIV-negative and obese, and 135 were HIV-negative and nonobese. Microbiome composition was assessed by targeted sequencing of the V4 region of the 16S ribosomal RNA (rRNA) gene using rectal swab samples. Inverse probability of treatment-weighted marginal structural models were used to investigate differences in microbial composition between groups while controlling for numerous clinical and behavioural confounders. Results: Significant variability in microbial composition was explained by the combination of HIV and obesity, over and above each condition alone (R2 for the marginal contribution of the H+/O+ group = 0.008; P = 0.001). H+O+ participants had the highest ratios of Prevotella to Bacteroides, a pro-inflammatory enterotype that has been described in HIV infection and obesity independently. H+O+ participants had lower levels of Bacteroides and Veillonella than all other groups, suggesting a synergistic effect of HIV and obesity on these genera. Conclusions: Our findings support the hypothesis that HIV and obesity act together to disrupt gut microbial communities, which may help explain higher levels of generalized inflammation among people living with both HIV and obesity.",
keywords = "HIV, inverse probability of treatment weighting, men who have sex with men, microbiome, obesity",
author = "Cook, {R. R.} and Fulcher, {J. A.} and Tobin, {N. H.} and F. Li and D. Lee and C. Woodward and M. Javanbakht and R. Brookmeyer and S. Shoptaw and R. Bolan and Aldrovandi, {G. M.} and Gorbach, {P. M.}",
note = "Funding Information: This work was supported by the National Institute on Drug Abuse (1R36 DA046310 and 2U01 DA036267) and the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS; National Institute of Mental Health P30 MH58107). Additional support was provided by the UCLA AIDS Institute and UCLA CFAR Microbiome and Mucosal Immunology Core (P30 AI028697). JAF was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) (K08 AI124979). Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co‐funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: This work was supported by the National Institute on Drug Abuse (1R36 DA046310 and 2U01 DA036267) and the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS; National Institute of Mental Health P30 MH58107). Additional support was provided by the UCLA AIDS Institute and UCLA CFAR Microbiome and Mucosal Immunology Core (P30 AI028697). JAF was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) (K08 AI124979). Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: {\textcopyright} 2019 British HIV Association",
year = "2020",
month = jul,
day = "1",
doi = "10.1111/hiv.12838",
language = "English (US)",
volume = "21",
pages = "365--377",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "6",
}